Foundation Fighting Blindness   Report issue

Foundation Phase 2
Founded: Columbia MD United States (1971)

Organization Overview

First Clinical Trial
2004
NCT00100230
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2022

Timeline

NOW
  • Now

Alternative names

Foundation Fighting Blindness | Foundation Fighting Blindness Clinical Research Institute

Active Ingredients

Drugs in Phase 2 Trials (4)

efalex (1 trial)

npi-001 (1 trial)

raav2.rep1 (1 trial)

valproic acid (depakene) (1 trial)

Drugs in Other Trials (3)

brinzolamide (azopt) (1 trial)

dorzolamide (trusopt) (1 trial)

vitamin a (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Choroideremia (Phase 2)

Genetic Diseases, Inborn (Phase 2)

Genetic Diseases, X-Linked (Phase 2)

Retinitis (Phase 2)

Retinitis Pigmentosa (Phase 2)

Syndrome (Phase 2)

Usher Syndromes (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 6
  • # of Trial APIs: 7